ALung Technologies Inc. has secured $12 million from investors. The Pittsburgh-based medical device company is working toward U.S. regulatory approval of its artificial lung.
The company’s device has been sold in Europe since 2014, 17 countries in total now including Canada and Australia, and the next step is FDA clearance, which the company reportedly expects to have by 2018 or 2019.
Behavioral Health, Interoperability and eConsent: Meeting the Demands of CMS Final Rule Compliance
In a webinar on April 16 at 1pm ET, Aneesh Chopra will moderate a discussion with executives from DocuSign, Velatura, and behavioral health providers on eConsent, health information exchange and compliance with the CMS Final Rule on interoperability.
ALung’s product, Hemolung RAS, removes carbon dioxide and delivers oxygen to the blood, allowing a patient in respiratory distress to avoid a ventilator or limit time on a ventilator. Time using a ventilator can hurt lung tissue over time.
According to Trib Live, ALung’s CEO Peter DeComo said the money was raised by wealthy individuals in Western Pennsylvania as opposed to venture capital firms.
Because of an FDA regulation that allows the use of an unapproved device in life-threatening situations with no alternatives, Hemolung RAS has already been used in several U.S. hospitals, including UPMC facilities in Pittsburgh.
